TY - JOUR
T1 - Methotrexate treatment protocols and the central nervous system
T2 - Significant cure with significant neurotoxicity
AU - Shuper, Avinoam
AU - Stark, Batya
AU - Kornreich, Liora
AU - Cohen, Ian J.
AU - Aviner, Shraga
AU - Steinmetz, Adam
AU - Stein, Jeremiah
AU - Goshen, Yaacov
AU - Yaniv, Isaac
PY - 2000/1/1
Y1 - 2000/1/1
N2 - Methotrexate can influence the central nervous system through several metabolic toxic pathways. These effects can be categorized as immediate, acute to subacute, or chronic neurologic syndromes. The acute to subacute syndrome occurs frequently in acute lymphoblastic leukemia treatment protocols, generally manifesting with focal neurologic signs and changes seen on magnetic resonance imaging and single photon emission computed tomography. While in some patients the neurotoxicity is transient and benign and allows for continuation of chemotherapy, in others it can be quite severe and debilitating, leading to permanent neurologic deficits. The need to modify the treatment protocols when neurotoxicity appears is not fully established. It is also unknown whether the use of sufficient amounts of leucovorin can overcome the toxic effects of the drug.
AB - Methotrexate can influence the central nervous system through several metabolic toxic pathways. These effects can be categorized as immediate, acute to subacute, or chronic neurologic syndromes. The acute to subacute syndrome occurs frequently in acute lymphoblastic leukemia treatment protocols, generally manifesting with focal neurologic signs and changes seen on magnetic resonance imaging and single photon emission computed tomography. While in some patients the neurotoxicity is transient and benign and allows for continuation of chemotherapy, in others it can be quite severe and debilitating, leading to permanent neurologic deficits. The need to modify the treatment protocols when neurotoxicity appears is not fully established. It is also unknown whether the use of sufficient amounts of leucovorin can overcome the toxic effects of the drug.
UR - http://www.scopus.com/inward/record.url?scp=0033799358&partnerID=8YFLogxK
U2 - 10.1177/088307380001500902
DO - 10.1177/088307380001500902
M3 - Article
AN - SCOPUS:0033799358
SN - 0883-0738
VL - 15
SP - 573
EP - 580
JO - Journal of Child Neurology
JF - Journal of Child Neurology
IS - 9
ER -